S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
S&P 500   5,062.98 (+0.02%)
DOW   37,900.13 (+0.44%)
QQQ   431.09 (+0.01%)
AAPL   168.45 (-2.46%)
MSFT   415.73 (+0.51%)
META   501.93 (+0.34%)
GOOGL   154.77 (-0.06%)
AMZN   183.81 (+0.10%)
TSLA   156.58 (-3.03%)
NVDA   867.80 (+0.91%)
AMD   162.80 (+1.55%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   16.05 (-1.17%)
F   12.09 (-1.14%)
MU   120.48 (-0.73%)
GE   154.85 (+0.75%)
CGC   6.98 (+0.00%)
DIS   114.01 (+0.94%)
AMC   2.68 (+8.50%)
PFE   25.83 (-0.31%)
PYPL   63.87 (+0.57%)
XOM   118.83 (-0.71%)
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

$15.59
+0.20 (+1.30%)
(As of 12:04 PM ET)
Today's Range
$15.16
$15.69
50-Day Range
$13.18
$17.01
52-Week Range
$11.09
$18.22
Volume
266,333 shs
Average Volume
1.41 million shs
Market Capitalization
$1.84 billion
P/E Ratio
25.56
Dividend Yield
N/A
Price Target
$26.43

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.7% Upside
$26.43 Price Target
Short Interest
Bearish
6.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.83mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$803,000 Sold Last Quarter
Proj. Earnings Growth
20.44%
From $1.81 to $2.18 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

8th out of 928 stocks

Pharmaceutical Preparations Industry

3rd out of 434 stocks

CPRX stock logo

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

CPRX Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Catalyst Pharmaceuticals, Inc.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CPRX Apr 2024 12.500 call
CPRX Apr 2024 17.500 put
CPRX Apr 2024 20.000 put
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CPRX
Employees
167
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$26.43
High Stock Price Target
$34.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+69.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$71.41 million
Pretax Margin
23.73%

Debt

Sales & Book Value

Annual Sales
$398.20 million
Cash Flow
$2.11 per share
Book Value
$3.30 per share

Miscellaneous

Free Float
103,732,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
0.89

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price target for 2024?

5 analysts have issued 1-year target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $23.00 to $34.00. On average, they anticipate the company's share price to reach $26.43 in the next year. This suggests a possible upside of 71.7% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2024?

Catalyst Pharmaceuticals' stock was trading at $16.81 at the start of the year. Since then, CPRX shares have decreased by 8.4% and is now trading at $15.39.
View the best growth stocks for 2024 here
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.04. The biopharmaceutical company earned $110.57 million during the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 26.56% and a net margin of 17.93%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Juncture Wealth Strategies LLC (0.08%), Los Angeles Capital Management LLC (0.07%), Strategic Advocates LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners